Complement dysregulation in thrombotic microangiopathy and the emerging role of Eculizumab
Dr. Anita Hill, a hematologist with extensive expertise in the management of PNH and aHUS/TTP using eculizumab shares with us an outstanding lecture on Primary Thrombotic Microangiopathies and the Role of Complement.
Complement dysregulation is an important process in the pathophysiology of atypical HUS/TTP. Targeting this important mechanistic step with eculizumab - a novel antibody against a terminal complement protein - might have an important role in the management of this rare and challenging clinical problem.
Dr. Hill will also take your questions related to this presentation which you can post in the UKidney Ask the Experts Forum using this link.
